Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

BIIBVery BearishCorporate Developmentsnews

High materiality8/10

BIIB122 Fails Phase 2b Study, Development Ceased for Parkinson's Disease

May 21, 2026, 6:03 PM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The failure of a drug in development typically leads to declines in stock price, especially when it affects investor sentiment and future growth potential.

AI summary

What happened, with direct paths to the underlying reporting

Biogen's investigational drug BIIB122, aimed at treating early-stage Parkinson's disease, has failed to meet its endpoints in the Phase 2b LUMA study. Consequently, Biogen and Denali will discontinue its development, impacting BIIB's future growth potential significantly in the neurodegenerative treatment space.

BIIB122 failed Phase 2b LUMA study in early Parkinson's disease.
Biogen and Denali will cease development of BIIB122 for idiopathic Parkinson's disease.
Denali will continue its Phase 2a BEACON study for a specific LRRK2 variant.
BIIB122 showed 90% kinase inhibition but lacked clinical efficacy.
Further findings from LUMA will be presented at a scientific conference.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

BIIB122 Fails Phase 2b Study, Development Ceased for Parkinson's Disease

Biogen-Eisai LEQEMBI IQLIK approval; diranersen Phase 2 data raises questions

FDA approves at-home starting dose for Leqembi, boosting access and uptake

Biogen to acquire RayThera for up to $1B, expanding immunology pipeline

Italy Opens Antitrust Probe into Biogen Italia Over Dominant-Position Allegations